Table 2.
Baseline characteristics and procedural details.
| Group 1 (*1/*1) n = 1682 | Group 2 (*1/*R) n = 2171 | Group 3 (*R/*R) n = 636 | p-value | |
|---|---|---|---|---|
| Age (year) | 64.4 ± 10.7 | 64.53 ± 10.67 | 64.41 ± 10.95 | 0.93 |
| Men, n (%) | 1186 (70.5) | 1545 (71.2) | 441 (69.3) | 0.78 |
| Body mass index (kg/m2) | 24.65 ± 3.11 | 24.6 ± 3.14 | 24.66 ± 3.12 | 0.86 |
| Current smoker, n (%) | 422 (25.1) | 564 (26.0) | 163 (25.6) | 0.83 |
| Hypertension, n (%) | 1065 (63.3) | 1374 (63.3) | 385 (60.5) | 0.32 |
| Diabetes mellitus, n (%) | 534 (31.8) | 733 (33.7) | 201 (31.6) | 0.67 |
| Hyperlipidaemia, n (%) | 621 (36.9) | 813 (37.5) | 236 (37.2) | 0.84 |
| Prior myocardial infarction, n (%) | 117 (7.0) | 161 (7.4) | 40 (6.3) | 0.80 |
| Prior PCI, n (%) | 239 (14.2) | 300 (13.8) | 91 (14.3) | 0.95 |
| Prior CABG, n (%) | 35 (2.1) | 34 (1.6) | 5 (0.8) | 0.03 |
| Prior cerebrovascular accident, n (%) | 118 (7.0) | 171 (7.9) | 41 (6.5) | 1.00 |
| Diagnosis at the index PCI | ||||
| Stable angina, n (%) | 682 (40.6) | 870 (40.1) | 248 (39.0) | 0.24 |
| Unstable angina, n (%) | 518 (30.8) | 691 (31.8) | 215 (33.8) | |
| NSTEMI, n (%) | 225 (13.4) | 268 (12.3) | 79 (12.4) | |
| STEMI, n (%) | 140 (8.3) | 194 (8.9) | 51 (8.0) | |
| Angiographic features | ||||
| Multivessel disease, n (%) | 310 (18.4) | 390 (18.0) | 119 (18.7) | 0.99 |
| Left main disease, n (%) | 72 (4.3) | 84 (3.9) | 28 (4.4) | 0.90 |
| Left anterior descending artery, n (%) | 998 (59.3) | 1309 (60.3) | 382 (60.1) | 0.64 |
| Type B2/C lesion, n (%) | 1655 (74.5) | 2116 (75.1) | 617 (74.5) | 0.96 |
| Reference vessel diameter (mm) | 2.99 ± 0.53 | 2.98 ± 0.65 | 3.04 ± 1.41 | 0.17 |
| Minimal lumen diameter (mm) | 0.62 ± 0.47 | 0.62 ± 0.44 | 0.62 ± 0.45 | 0.95 |
| Diameter stenosis (%) | 79.25 ± 17.92 | 78.89 ± 23.13 | 79.16 ± 14.65 | 0.83 |
| Lesion length (mm) | 24.7 ± 12.68 | 25.06 ± 12.97 | 24.08 ± 11.88 | 0.17 |
| Procedural data | ||||
| Bare metal stent, n (%) | 2 (0.1) | 4 (0.1) | 1 (0.1) | 0.37 |
| First-generation drug-eluting stent, n (%) | 3 (0.1) | 7 (0.2) | 2 (0.2) | |
| Second-generation drug-eluting stent, n (%) | 1636 (64.5) | 2069 (63.6) | 590 (61.8) | |
| Third-generation drug-eluting stent, n (%) | 803 (31.7) | 1046 (32.1) | 330 (34.6) | |
| Stent diameter (mm) | 3.03 ± 0.48 | 3.02 ± 0.45 | 3.02 ± 0.43 | 0.80 |
| Stent length (mm) | 24.27 ± 7.99 | 24.28 ± 8.27 | 23.92 ± 7.88 | 0.45 |
| Stent number (/patient) | 1.34 ± 0.63 | 1.31 ± 0.6 | 1.29 ± 0.58 | 0.53 |
| P2Y12 reaction units | 191.21 ± 76.98 | 221.46 ± 70.97 | 249.8 ± 71.01 | <0.01 |
| Other laboratory findings | ||||
| Haemoglobin (g/dL) | 13.6 ± 1.89 | 13.69 ± 1.8 | 13.66 ± 1.92 | 0.36 |
| Platelet count (×1,000/µL) | 228.02 ± 63.79 | 228.88 ± 63.83 | 225.72 ± 64.24 | 0.55 |
| AST (IUI/L) | 32.16 ± 36.16 | 32.33 ± 40.83 | 34.34 ± 50.19 | 0.50 |
| ALT (IUI/L) | 26.9 ± 31.56 | 25.18 ± 19.38 | 25.9 ± 24.12 | 0.12 |
| Total cholesterol (mg/dL) | 172.7 ± 45.89 | 173.1 ± 43.98 | 173.26 ± 45.72 | 0.95 |
| LDL-C (mg/dL) | 103.38 ± 36.68 | 104.29 ± 36.88 | 104.99 ± 38.05 | 0.64 |
| HDL-C (mg/dL) | 42.58 ± 11.53 | 42.6 ± 11.49 | 42.81 ± 11.3 | 0.91 |
| Triglyceride (mg/dL) | 142.47 ± 105.59 | 144.21 ± 93.71 | 139.1 ± 108.24 | 0.56 |
| Fasting glucose (mg/dL) | 128.73 ± 51.81 | 131.06 ± 51.77 | 131.73 ± 56.11 | 0.35 |
| Creatinine (mg/dL) | 1.04 ± 0.93 | 1.04 ± 0.87 | 1.28 ± 2.09 | <0.01 |
| hsCRP (mg/L) | 4.64 ± 18.31 | 3.68 ± 13.09 | 5.19 ± 25.84 | 0.24 |
| Left ventricular ejection fraction (%) | 58.53 ± 11.08 | 59.06 ± 11.04 | 59.15 ± 11.02 | 0.30 |
| Discharge medication | ||||
| Aspirin, n (%) | 1675 (99.6) | 2157 (99.5) | 632 (99.5) | 0.77 |
| Clopidogrel, n (%) | 1647 (97.9) | 2131 (98.3) | 625 (98.4) | 0.34 |
| Proton pump inhibitor, n (%) | 244 (14.5) | 375 (17.3) | 97 (15.3) | 0.23 |
| Statin, n (%) | 1575 (93.6) | 2018 (93.1) | 605 (95.3) | 0.36 |
| ACE inhibitor, n (%) | 472 (28.1) | 571 (26.4) | 163 (25.7) | 0.17 |
| ARB, n (%) | 574 (34.2) | 746 (34.4) | 213 (33.7) | 0.93 |
| Beta-blocker, n (%) | 1054 (62.7) | 1300 (60.0) | 402 (63.3) | 0.70 |
Data were presented as n (%) or mean ± standard deviation. Abbreviations: PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker. *R represents *2 or *3.